The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...

Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Researchers, public health and health care groups, advocates, industry, and the public must put tackling diet-related disease ...

Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI™ (dexmedetomidine ... treatment of agitation associated with bipolar I or II disorder or schizophrenia in the ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Reviva Pharmaceuticals (RVPH) announced an enrollment update to the ongoing 1-year open-label extension, OLE, study evaluating the long-term safety and tolerability of brilaroxazine in patients with ...

"These results have clear positive read-through to Bristol Myers," wrote William Blair analysts Matt Phipps and Myles Minter in a note released Monday, pointing to the recent Food and Drug ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia ...